PCSK9 inhibitors – Medxy AI

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine

By MedXY 03/25/2026

This review synthesizes the trajectory of PCSK9 inhibitors, from pivotal monoclonal antibody trials to emerging RNA interference and gene-editing technologies, emphasizing their role in achieving ultra-low LDL-C levels and reducing major adverse cardiovascular events.

Cardiology Internal Medicine news

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

By MedXY 03/21/2026

This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefining the boundaries of LDL-C reduction and patient care in atherosclerotic disease.

Cardiology news

High Lipoprotein(a) Predicts Recurrent ASCVD — Intensified LDL‑Lowering, Especially PCSK9 Inhibitors, May Attenuate Risk

By MedXY 12/02/2025

In 273,770 US patients with established ASCVD, rising lipoprotein(a) (nmol/L) was steadily associated with higher risk of recurrent events; the excess risk was partially blunted in those receiving high‑impact LDL‑lowering therapy, most notably PCSK9 inhibitors.

Cardiology news

PCSK9 Inhibition Prevents First Major Cardiovascular Events: VESALIUS‑CV trial

By MedXY 11/09/2025

In the VESALIUS‑CV trial, evolocumab reduced first major adverse cardiovascular events by 25% (3‑point MACE) and 19% (4‑point MACE) versus placebo over 4.6 years in patients with atherosclerosis or diabetes and no prior MI or stroke.